Just read this on reddit/CYDY. Instructive and hopeful!
------------
From "u/upwithstock":
HIV and LH market
As I have stated before about a successful BioPharma company; success boils down to three things: 1) Good data 2) Regulatory approvals 3) Revenue generating distribution. We are close on COVID outside of the U.S. I am confident that CYDY will begin to see some sort of approvals from different countries that allow them to generate revenues: Philippines, Canada, India and Brazil with more on the way. But, I want to draw your attention to HIV and Long Haulers.
In the U.S. we are moving closer on two indications that are at different stages but represent very large markets; 1) HIV and 2) Long Haulers also referred as PACS. As most of you know CYDY and n-particular Dr. Recknor are filing the corrected BLA in July. If this gets accepted by the FDA a PDUFA date will be scheduled out approximately six months later making January/February 2022 timeline for final FDA review/approval. Synthesis 1 has CYDY's market potential listed at $14 billion and that was conservative.
Number two and much bigger is the Long haulers/PACS market. Scott Kelly estimated 20-60 Million patients world wide. Not including the new variants that are circulating. Nonetheless, if you assume that Leronlimab treats 10 million patients (assuming some folks can't afford treatment) at 8 shots per patients (LH Phase 2 protocol) at $1K per shot that would be $8K per patient times 10 million patients and you're looking at $80 Billion. This easily would put CYDY in the top three Pharma companies in the world just with LHers.
I am not selling !!
----------------
